Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
Stopped early · Phase 3
Conditions studied: Prostate Cancer
In brief
RATIONALE: Zoledronate may be able to prevent bone metastases caused by prostate cancer. It is not yet known if zoledronate is effective in preventing the spread of prostate cancer to the bones. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate plus standard therapy in preventing bone metastases in patients who have recurrent prostate cancer that is not causing symptoms.
Key facts
- Study ID
- NCT00005073
- Run by
- Novartis Pharmaceuticals
- People needed
- 544
- Starts
- 1999-09-01
- Expected to finish
- 2003-03-01
- Last updated by the study team
- 2013-05-01
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.